| Literature DB >> 34706716 |
Jinwei Cai1,2,3, Cuiting Lin4,5, Shuiqing Lai2, Yingshan Liu1,2, Min Liang3, Yingfen Qin3, Xinghuan Liang3, Aihua Tan6, Yong Gao6, Zheng Lu6, Chunlei Wu6, Shengzhu Huang1,5,7, Xiaobo Yang6, Haiying Zhang6, Jian Kuang8,9, Zengnan Mo6,7,10,11.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has been entitled as metabolic-dysfunction associated fatty liver disease (MAFLD). Therefore anthropometric indicators of adiposity may provide a non-invasive predictive and diagnostic tool for this disease. This study intended to validate and compare the MAFLD predictive and diagnostic capability of eight anthropometric indicators.Entities:
Keywords: Abdominal volume index; Anthropometric indicator; Lipid accumulation product; Metabolic-dysfunction associated fatty liver disease; Non-alcoholic fatty liver disease; Visceral fat; Waist-to-height ratio
Mesh:
Year: 2021 PMID: 34706716 PMCID: PMC8549212 DOI: 10.1186/s12944-021-01568-9
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1Flowchart of the study participants and exclusions
Cut-off points and AUCs (95% CI) of different anthropometric indicators and HOMA-index in predicting MAFLD (n = 2355)
| Parameters | AUC (95% CI) | Cut-off point | Sensitivity (%) | Specificity (%) | |
|---|---|---|---|---|---|
| BMI | 0.846 (0.829–0.864) | < 0.001 | 24.00 | 84.08 | 72.39 |
| WHtR | 0.863 (0.848–0.879) | < 0.001 | 0.49 | 90.68 | 69.56 |
| WHR | 0.814 (0.796–0.833) | < 0.001 | 0.89 | 84.46 | 64.95 |
| BAI | 0.790 (0.769–0.810) | < 0.001 | 24.97 | 71.70 | 72.50 |
| CMI | 0.819 (0.800–0.838) | < 0.001 | 0.48 | 81.75 | 69.24 |
| LAP | 0.868 (0.853–0.883) | < 0.001 | 24.29 | 86.60 | 74.73 |
| VAI | 0.807 (0.787–0.826) | < 0.001 | 0.94 | 81.20 | 67.23 |
| AVI | 0.859 (0.843–0.874) | < 0.001 | 13.61 | 89.71 | 68.86 |
| HOMA-IR | 0.803 (0.783–0.824) | < 0.001 | 1.69 | 81.36 | 68.91 |
| HOMA-β | 0.715 (0.690–0.740) | < 0.001 | 78.10 | 76.31 | 57.18 |
Abbreviations: MAFLD Metabolic-dysfunction associated fatty liver disease, BMI Body mass index, WHtR Waist to height ratio, WHR Waist to hip ratio, BAI Body adiposity index, CMI Cardiometabolic index, LAP Lipid accumulation product, VAI Visceral adiposity index, AVI Abdominal volume index, HOMA Homeostatic model assessment, AUC Area under the ROC curves, P < 0.05 was accepted statistically significant
Baseline characteristics in study male population
| Characteristics | Total | MAFLD | Non-MAFLD | |
|---|---|---|---|---|
| Age (years) | 37.82 ± 11.10 | 39.84 ± 9.92 | 37.26 ± 11.35 | < 0.001 |
| Height (cm) | 167.97 ± 5.54 | 167.98 ± 5.61 | 167.97 ± 5.53 | 0.967 |
| Weight (kg) | 65.87 ± 10.43 | 74.85 ± 9.58 | 63.36 ± 9.21 | < 0.001 |
| WC (cm) | 80.87 ± 9.23 | 89.90 ± 6.75 | 78.34 ± 8.19 | < 0.001 |
| HC (cm) | 91.51 ± 6.20 | 96.56 ± 5.59 | 90.10 ± 5.60 | < 0.001 |
| SBP (mmHg) | 118.32 ± 15.48 | 123.53 ± 17.00 | 116.87 ± 14.70 | < 0.001 |
| DBP (mmHg) | 77.00 ± 10.25 | 81.23 ± 11.34 | 75.82 ± 9.60 | < 0.001 |
| ALT (U/L) | 39.00 (30.00–54.00) | 54.00 (40.00–74.00) | 36.00 (29.00–48.00) | < 0.001 |
| TC (mmol/L) | 5.71 ± 1.03 | 6.08 ± 1.03 | 5.60 ± 1.00 | < 0.001 |
| TG (mmol/L) | 1.13 (0.78–1.75) | 1.88 (1.31–2.79) | 1.00 (0.71–1.48) | < 0.001 |
| HDL (mmol/L) | 1.40 ± 0.33 | 1.29 ± 0.40 | 1.44 ± 0.30 | < 0.001 |
| LDL (mmol/L) | 2.97 ± 0.80 | 3.28 ± 0.78 | 2.88 ± 0.79 | < 0.001 |
| UA (μmol/L) | 378.46 ± 79.68 | 420.29 ± 87.04 | 366.76 ± 73.37 | < 0.001 |
| FPG (mmol/L) | 5.20 (4.90–5.60) | 5.40 (5.00–5.80) | 5.10 (4.90–5.50) | < 0.001 |
| Insulin (mU/L) | 6.38 (4.27–9.67) | 10.46 (7.57–15.22) | 5.61 (3.85–8.19) | < 0.001 |
| HOMA-IR | 1.47 (0.97–2.31) | 2.55 (1.80–3.75) | 1.29 (0.87–1.90) | < 0.001 |
| HOMA-IS | 0.68 (0.43–1.03) | 0.39 (0.27–0.56) | 0.78 (0.53–1.14) | < 0.001 |
| HOMA-β(%) | 78.35 (49.82–118.33) | 115.08 (79.45–164.45) | 69.82 (45.86–104.74) | < 0.001 |
| FSH (mIU/mL) | 5.10 (3.58–7.53) | 5.06 (3.63–7.53) | 5.12 (3.56–7.54) | 0.804 |
| LH (mIU/mL) | 5.18 (3.97–6.72) | 4.89 (3.67–6.42) | 5.27 (4.05–6.81) | < 0.001 |
| Estradiol (pg/mL) | 34.34 ± 10.13 | 32.58 ± 8.73 | 34.84 ± 10.44 | < 0.001 |
| Testosterone (ng/mL) | 6.26 ± 1.93 | 4.92 ± 1.48 | 6.64 ± 1.87 | < 0.001 |
| SHBG (nmol/L) | 38.35 (28.02–51.28) | 25.84 (19.43–35.04) | 41.97 (32.10–54.44) | < 0.001 |
Abbreviations: MAFLD Metabolic-dysfunction associated fatty liver disease, WC Waist circumference, HC HIP circumference, SBP Systolic blood pressure, DBP Diastolic blood pressure, ALT Alanine transaminase, TC Total cholesterol, TG Triglyceride, HDL High-density lipoprotein, LDL Low-density lipoprotein, UA Uric acid, FPG Fasting plasma glucose, HOMA Homeostatic model assessment, FSH Follicle stimulating hormone, LH Luteinizing hormone, SHBG Sex hormone-binding globulin. Numeric variables are described by (mean ± SD) or median (interquartile range). P < 0.05 was accepted statistically significant
Means ± standard deviations and medians (interquartile range) for the anthropometric indicators in individuals. (n = 2355)
| Total | MAFLD | Non-MAFLD | |||
|---|---|---|---|---|---|
| BMI | 23.32 ± 3.35 | 26.49 ± 2.82 | 22.44 ± 2.92 | 786.688 | < 0.001 |
| WHtR | 0.48 ± 0.05 | 0.54 ± 0.04 | 0.46 ± 0.05 | 887.109 | < 0.001 |
| WHR | 0.88 ± 0.06 | 0.93 ± 0.05 | 0.87 ± 0.05 | 583.939 | < 0.001 |
| BAI | 24.08 ± 2.94 | 26.39 ± 2.65 | 23.43 ± 2.68 | 493.532 | < 0.001 |
| CMI | 0.39 (0.24–0.72) | 0.84 (0.54–1.28) | 0.32 (0.21–0.55) | −22.183 | < 0.001 |
| LAP | 17.09 (7.02–37.00) | 45.24 (30.97–71.40) | 12.09 (5.40–24.61) | −25.596 | < 0.001 |
| VAI | 0.81 (0.50–1.43) | 1.64 (1.02–2.60) | 0.68 (0.45–1.13) | −21.308 | < 0.001 |
| AVI | 13.35 ± 2.99 | 16.30 ± 2.45 | 12.52 ± 2.58 | 881.957 | < 0.001 |
Abbreviations: MAFLD Metabolic-dysfunction associated fatty liver disease, BMI Body mass index, WHtR Waist to height ratio, WHR Waist to hip ratio, BAI Body adiposity index, CMI Cardiometabolic index, LAP Lipid accumulation product, VAI Visceral adiposity index, AVI Abdominal volume index. Numeric variables are described by (mean ± SD) or median (interquartile range). P < 0.05 was accepted statistically significant
Fig. 2ROC-curves of different adipose tissue accumulation indicators and HOMA-index associate with MAFLD. Abbreviations: MAFLD: Metabolic-dysfunction associated fatty liver disease; BMI: Body; mass index; WHtR: Waist to height ratio; WHR: Waist to hip ratio; BAI: Body adiposity; index; CMI: Cardiometabolic index; LAP: Lipid accumulation product; VAI: Visceral; adiposity index; AVI: Abdominal volume index; HOMA: Homeostatic model assessment; IR: Insulin resistance
Spearman rank correlation analysis of anthropometric indicators and sex hormones in MAFLD Population (n = 515)
| Variable | SHBG | FSH | LH | E2 | TT | HOMA-IR | HOMA-β | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI | −0.173 | < 0.001 | −0.017 | 0.707 | −0.052 | 0.243 | 0.133 | 0.003 | −0.212 | < 0.001 | 0.420 | < 0.001 | 0.332 | < 0.001 |
| WHtR | −0.083 | 0.061 | 0.132 | 0.003 | 0.041 | 0.358 | 0.100 | 0.023 | − 0.214 | < 0.001 | 0.401 | < 0.001 | 0.294 | < 0.001 |
| WHR | −0.045 | 0.307 | 0.209 | < 0.001 | 0.105 | 0.018 | −0.022 | 0.612 | −0.187 | < 0.001 | 0.302 | < 0.001 | 0.164 | < 0.001 |
| BAI | −0.070 | 0.112 | −0.021 | 0.631 | −0.049 | 0.269 | 0.120 | 0.006 | −0.128 | 0.004 | 0.246 | < 0.001 | 0.244 | < 0.001 |
| CMI | −0.264 | < 0.001 | −0.043 | 0.327 | −0.028 | 0.522 | −0.062 | 0.159 | −0.279 | < 0.001 | 0.334 | < 0.001 | 0.217 | < 0.001 |
| LAP | −0.274 | < 0.001 | 0.007 | 0.869 | −0.033 | 0.455 | −0.064 | 0.147 | −0.324 | < 0.001 | 0.431 | < 0.001 | 0.247 | < 0.001 |
| VAI | −0.278 | < 0.001 | − 0.072 | 0.101 | − 0.049 | 0.265 | − 0.055 | 0.211 | − 0.273 | < 0.001 | 0.323 | < 0.001 | 0.210 | < 0.001 |
| AVI | −0.119 | 0.007 | 0.100 | 0.023 | 0.002 | 0.958 | 0.127 | 0.004 | −0.223 | < 0.001 | 0.423 | < 0.001 | 0.306 | < 0.001 |
Abbreviations: MAFLD Metabolic-dysfunction associated fatty liver disease, BMI Body mass index, WHtR Waist to height ratio, WHR Waist to hip ratio, BAI Body adiposity index, CMI Cardiometabolic index, LAP Lipid accumulation product, VAI Visceral adiposity index, AVI Abdominal volume index, SHBG Sex hormone-binding globulin, FSH Follicle stimulating hormone, LH Luteinizing hormone, E2 Estradiol, TT Testosterone, HOMA Homeostatic model assessment. P < 0.05 was accepted statistically significant
Binary logistic regression analysis of anthropometric indicators and HOMA-index in predicting MAFLD (n = 2355)
| Variable | Non-adjusted | Model I | Model II | Model III | ||||
|---|---|---|---|---|---|---|---|---|
| OR(95% CI) | OR(95% CI) | OR(95% CI) | OR(95% CI) | |||||
| BMI | 13.722 (10.620–17.729) | < 0.001 | 12.768 (9.866–16.525) | < 0.001 | 7.431 (5.635–9.800) | < 0.001 | 5.019 (3.751–6.715) | < 0.001 |
| WHtR | 22.181 (16.216–30.340) | < 0.001 | 21.441 (15.575–29.516) | < 0.001 | 12.454 (8.880–17.466) | < 0.001 | 7.795 (5.492–11.064) | < 0.001 |
| WHR | 10.050 (7.773–12.994) | < 0.001 | 9.583 (7.335–12.521) | < 0.001 | 5.468 (4.107–7.280) | < 0.001 | 3.924 (2.912–5.287) | < 0.001 |
| BAI | 6.663 (5.362–8.280) | < 0.001 | 6.248 (5.013–7.786) | < 0.001 | 4.014 (3.159–5.099) | < 0.001 | 2.922 (2.267–3.767) | < 0.001 |
| CMI | 10.081 (7.894–12.874) | < 0.001 | 9.459 (7.394–12.101) | < 0.001 | 4.969 (3.589–6.880) | < 0.001 | 3.288 (2.339–4.621) | < 0.001 |
| LAP | 16.856 (12.825–22.155) | < 0.001 | 15.734 (11.952–20.714) | < 0.001 | 9.029 (6.560–12.426) | < 0.001 | 6.077 (4.345–8.501) | < 0.001 |
| VAI | 8.818 (6.927–11.226) | < 0.001 | 8.331 (6.532–10.627) | < 0.001 | 3.933 (2.855–5.417) | < 0.001 | 2.685 (1.917–3.759) | < 0.001 |
| AVI | 19.275 (14.266–26.041) | < 0.001 | 18.107 (13.352–24.555) | < 0.001 | 10.359 (7.498–14.311) | < 0.001 | 6.537 (4.676–9.138) | < 0.001 |
| HOMA-IR | 9.675 (7.590–12.334) | < 0.001 | 9.761 (7.634–12.481) | < 0.001 | 6.149 (4.689–8.064) | < 0.001 | 4.384 (3.298–5.828) | < 0.001 |
| HOMA-β | 4.281 (3.425–5.352) | < 0.001 | 4.710 (3.748–5.918) | < 0.001 | 3.594 (2.768–4.666) | < 0.001 | 2.792 (2.110–3.694) | < 0.001 |
Abbreviations: MAFLD Metabolic-dysfunction associated fatty liver disease, BMI Body mass index, WHtR Waist to height ratio, WHR Waist to hip ratio, BAI Body adiposity index, CMI Cardiometabolic index, LAP Lipid accumulation product, VAI Visceral adiposity index, AVI Abdominal volume index, HOMA Homeostatic model assessment, OR Odds ratio, CI Confidence interval. P < 0.05 was accepted statistically significant
Model I:Adjusted for age
Model II:Adjusted for age, blood glucose, blood pressure, plasma uric acid, lipid parameters (TC, TG, HDL-C, LDL-C)
Model III:Adjusted for age, blood glucose, blood pressure, plasma uric acid, lipid profile and sex hormone parameters (FSH, LH, E2, TT, SHBG)